Top news of the week: 03.04.2023.
Jan Skvarka, former Trillium CEO, on Driving a Turnaround
Jan Skvarka isn’t a household name in biotech. Maybe he should be. Skvarka was previously the CEO of Trillium Therapeutics, where he led a remarkable turnaround of the Canadian small cap ...
Timmerman Traverse for Life Science Cares is Back
The next biotech team adventure is here. I’m thrilled to announce the Timmerman Traverse for Life Science Cares 2023. We’re on a mission to raise $1 million. We’re giving it all back to the ...
Bicycle, Novartis Ink Oncology Deal Worth up to $1.7B
Bicycle Therapeutics and Novartis announced Tuesday they have inked a deal worth up to $1.7 billion to discover and develop targeted radioligand therapies in oncology.
Bicycle, Novartis Ink Oncology Deal Worth up to $1.7B
Bicycle Therapeutics and Novartis announced Tuesday they have inked a deal worth up to $1.7 billion to discover and develop targeted radioligand therapies in oncology.